Journey Medical Corp (DERM)
Journey Medical Corp is a commercial-stage pharmaceutical company focused on developing and marketing treatments for dermatological conditions in the United States. Its portfolio includes Qbrexza for primary axillary hyperhidrosis, Accutane for severe recalcitrant nodular acne, and Amzeeq for inflammatory lesions of moderate to severe acne vulgaris. The company also markets Zilxi and Emrosi for rosacea, Exelderm cream and solution for fungal skin infections, Targadox for adjunctive therapy in severe acne, and Luxamend, a water-based emulsion used to support moist wound healing for minor skin injuries, ulcers, burns, and radiation dermatitis. Formerly known as Coronado Dermatology, Inc., Journey Medical was incorporated in 2014 and is headquartered in Scottsdale, Arizona. The listed security is common stock on NASDAQ under the symbol DERM.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DERM
|
$6.60
|
-8.1% Downside
|
Fair
|
$13.50
|
87.9% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-20.6x
|
6.4x
|
3.1x
|
195.2 M
|
195.9 M
|
11.5%
|
54.1%
|
0.9
|
—
|
69.9%
|
